Investor Sentiment Declines Further After Dow Settles Lower

The CNN Money Fear and Greed index showed another decline in overall sentiment among US investors. US stocks closed mixed on Wednesday after recording sharp losses in the previous session following comments from Federal Reserve Chair Jerome Powell.

The CNN Money Fear and Greed index showed another decline in overall sentiment among US investors.

US stocks closed mixed on Wednesday after recording sharp losses in the previous session following comments from Federal Reserve Chair Jerome Powell.

Investors assessed the economic data, which showed private businesses in the US adding 242,000 jobs in February versus a revised 119,000 gain in January and above market expectations of 200,000. The number of job openings fell by 410,000 to 10.824 million in January.

The Dow closed lower by around 58 points to 32,798.40 on Wednesday. The S&P 500 rose 0.14% to 3,992.01, while the Nasdaq Composite gained 0.40% to settle at 11,576.00 during the session.

Investors are awaiting earnings results from BJ’s Wholesale Club Holdings, Inc. (NYSE:BJ), Oracle Corporation (NYSE:ORCL) and JD.com, Inc. (NASDAQ:JD) today.

At a current reading of 46.0, the index remained in the “Neutral” zone, compared to a previous reading of 48.0.

What is CNN Business Fear & Greed Index?

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

Read Next: Top 5 Consumer Stocks That May Rocket Higher

Total
0
Shares
Related Posts
Read More

Johnson & Johnson Unit Janssen Announced New VOYAGER PAD Analysis Confirms Consistent Benefit Of XARELTO Plus Aspirin Following Lower Extremity Revascularization

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following

JNJ